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ABSTRACT 
Mutlazima Qabl Haiz (Premenstrual syndrome) refers to a combination of physical and emotional disturbances that occur after a 
woman ovulates and resolves with start of menstruation. More than 200 symptoms have been ascribed to PMS. Premenstrual 
Dysphoric Disorder is a more severe form of premenstrual syndrome. The characteristic symptoms of premenstrual syndrome are 
mood swings, anxiety, and irritability and physical conditions – like headache, fatigue, bloating, sleep disturbances, nausea, and 
breast tenderness. 90% of the women all over the world experience these symptoms during their reproductive years. The PMS has 
unknown cause and does not have any specific proved diagnosis and medication in modern medicine. The main objective of this 
article is to review the potential treatment for premenstrual syndrome in Unani medicine. 
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INTRODUCTION  
The luteal phase of menstrual cycle starts from the time 
of ovulation and ends at the onset of menses. Some 
women experience physical, emotional and 
psychological symptoms during their luteal phase and 
beginning of their menstrual bleeding that are known as 
premenstrual syndrome.
 1 
The psychological symptoms 
include irritability, mood swings, depressed mood, 
crying spells, low self-esteem, anxiety, sleep 
disturbance, increased appetite, lethargy or fatigue; 
cognitive symptoms include forgetfulness, decreased 
concentration and physical symptoms include breast 
tenderness, bloating, fluid retention, weight gain, 
constipation, hot flushes, headaches, musculoskeletal 
discomfort, acne, rhinitis, palpitation.
2 
Approximately 
40% of women experience luteal phase symptoms 
during menstrual cycle that are troublesome; for 25% 
these are irritating but do not impair functioning; for 10-
15%, the symptoms are severe with significant 
impairment in daily life activities 
3,4 
It has also been 
found that the prevalence of premenstrual syndrome 
(PMS) is higher in unmarried women, in women who 
belong to a low socioeconomic deprived areas and in 
women aged 35-44 years. 
5-6
 
SYMPTOMS OF PMS 
In 1931, Robert Frank used the term “Premenstrual 
Tension” for this phenomena.  Greene and Dalton in 
1953 called this condition as “Premenstrual Syndrome” 
to allow the inclusion of both somatic and psychological 
complaints in the symptom complex.
7
 Mutlazima Qabl 
Haiz is the term from the Arabic dictionary
8,9 
in which 
syndrome is translated as ‘mutlazima’, pre stands for 
‘qabl’ and menstrual is the word given for ‘haiz’. No 
such term was defined by ancient Unani scholars but 
they had given a description on premenstrual features. 
The ancient physicians mentioned that, imtelayi kaifiat 
present in the premenstrual phase which leads to number 
Naushin et al                                                                                                  Journal of Drug Delivery & Therapeutics. 2018; 8(5-s):122-125        
ISSN: 2250-1177                                                                            [123]                                                                             CODEN (USA): JDDTAO 
of features. It is well documented that surge of akhlat 
muharrika (hormones) are responsible for build up of 
body fluid in tissue spaces during premenstrual phase 
and this theory correlates with the concept given by 
IbnSina
10 
and others are as follows: 
 According to Zakariya Razi symptoms are anorexia, 
lassitude, anxiety, tremers and when these 
symptoms increase in intensity person  may also 
complain of pelvic pain, pica, headache, backache 
and vomiting.
11
 
 According to Ghulam Jeelani and Hakeem Ajmal 
Khan, the functions of liver get disturbed as a result 
of circulation of toxins in the blood during 
premenstrual phase, so that the person is unable to 
bear minor degrees of disturbances which lead to 
palpitation, headache and giddiness. These persons 
show temperament changes of melancholic type.
12,13
 
 According to Ibn Sina in Canon of Medicine under 
the heading of “Plethora (Imtila akhlat)” symptoms 
are anxiety, tension, headache, irritability, 
decreased concentration, insomnia, anorexia, 
palpitation, weight gain, food cravings, 
constipation, nausea, diarrhoea, puffiness of face, 
tingling in skin, and numbness in hand and leg.
10
 
ETIOLOGY OF PMS  
Although the underlying cause remains uncertain; seems 
to be multifactorial but ovarian hormone cycle appears 
to be important factor, since premenstrual syndrome is 
not observed before puberty in girls and after 
menopause in women. Some theories have been 
suggested to explain the pathophysiology of severe PMS 
as follows. 
1. Ovarian hormone theory: The PMS is only 
observed in the women of reproductive age, it is 
supposed that the female gonadal hormones play a 
causative role, possibly mediated through the alteration 
of serotoninergic activity in the brain. This theory 
hypothesises that imbalance in the estrogen to 
progesterone ratio is the cause of PMS, with a relative 
deficiency in progesterone.
15
 Trial has shown that 
administration of progesterone hormone during the 
premenstrual phase of the menstrual cycle can decrease 
the severity of premenstrual symptoms in some women. 
16
 
2. Deficiency of Neurotransmitter: This theory 
implicates the deficiency of neurotransmitters such as 
serotonin and gaminobutyric acid (GABA) as a cause of  
PMS. Serotonin receptors are responsive to estrogen and 
progesterone, and Serotonin deficiency has been 
postulated in PMS patients; as the symptoms of PMS 
respond to selective serotonin reuptake inhibitors 
(SSRIs), which increase the amount of circulating 
Serotonin. GABA levels are modulated by the, 
allopregnanolone, a metabolite of progesterone and in 
women with PMS the allopregnanolone levels appear to 
be reduced. 
17
 
MANAGEMENT 
PMS is prevalent in women of reproductive age causing 
substantial morbidity with obvious detriment to 
interpersonal relationships, social interactions, lifestyle, 
work performance, emotional well-being and overall 
health-related quality of life. 
18
 Treatment goals for PMS 
are to ameliorate or reduce symptoms, decrease their 
impact on daily activities and interpersonal 
relationships, and reduce adverse effects of treatment.  
1. Nonpharmacologic 
 Diet 
The usual recommendations are for a decrease in salt, 
sugar, alcohol and caffeine, and an increase in meals 
with a low glycaemic index. It is suggested that an 
increased complex carbohydrate intake increases brain 
serotonin activity, which in turn improves symptoms. 
 Exercise 
Aerobic activity leads to increased endorphin levels, 
which are known to improve mood, and several studies 
recommend there may be some benefit in the treatment 
of PMS. 
19
 
 Cognitive Behavior Therapy 
A 2009 meta-analysis analyzed seven trials, three of 
which were randomized controlled trials, and showed 
improvement in functioning and depression scores for 
patients with PMS or PMDD.
20
 
2. Pharmacologic: 
Pharmacologic therapies carry a greater risk of adverse 
events, and this must be considered when selecting such 
therapy, and should be only suggested to patients if 
symptoms are not adequately relieved by non-
pharmacologic measures. 
21
 
 Serotonergic Antidepressants: Medications 
affecting serotonin are first-line treatment of choice 
for severe PMS or PMDD 
22,23 
The selective 
serotonin reuptake inhibitors (SSRIs) citalopram 
(Celexa), escitalopram (Lexapro), fluoxetine 
(Prozac), and sertraline (Zoloft)—taken every day 
or only during the luteal phase of menstruation—
significantly decrease physical and psychological 
symptoms of PMS compared with placebo.
23
 
 Oral contraceptive pills (OCPs): Some women 
with the PMS are prescribed the OCPs to balance 
their ovarian hormones fluctuations. Research has 
reported that the new OCP formulations seem to be 
more beneficial and effective in the improvement of 
premenstrual symptoms. 
24, 25
 
 Suppression of ovarian cycle: Gonadotropin-
releasing hormone (GnRH) analogues suppress 
ovarian function and reduce disturbing premenstrual 
symptoms in some women. 
26  
However, it may not 
be used for more than six months due to its adverse 
effects, particularly hot flushes and decreased bone 
density.
22
 Androgenic agent like danazol inhibits 
gonadotropin release, thus improving mastalgia.
27 
Continuous danazol therapy may also relieve other 
PMS symptoms. However, long term therapy of 
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danazol is limited by side effects such as 
masculinization (e.g., weight gain, decreased breast 
size, deepening of the voice), as well as adverse 
effects on LFTs and serum lipid profiles.
 27,28
 
3. Supplements: Certain supplements have been 
reported to be efficient in the reduction of the severity 
and duration of the premenstrual symptoms. They are 
calcium supplements (1000 mg)
29
,magnesium (200 mg) 
30
, vitamin E (400 units), vitamin B6 (pyridoxine) 
31
, 
chaste berry (vitex agnus castus) 
32, St John’s Wort 33, 
evening primrose oil (3000–4000 mg) 26, Black Cohosh 
and Dandelion 
34
. It has been reported that these 
therapies need to be taken for at least two consecutive 
cycles to be effective. 
16,29,30
 High doses of supplements 
may be toxic and harm the liver in some individuals, so 
consult with their physicians before taking any 
supplements. 
35
 
MANAGEMENT PROTOCOL OF PMS 
The following steps for treating PMS are based on 
recommendations outlined in an ACOG Practice 
Bulletin: 
 Step 1:  
A. Mild/moderate symptoms: Supportive therapy with 
good nutrition, complex carbohydrates, aerobic exercise, 
calcium supplements, and possibly magnesium or chaste 
berry fruit.  
B. If physical symptoms predominate: NSAIDs or 
Spironolactone, or balance hormonal formulations with 
OCPs or medroxyprogesterone acetate.  
 Step 2:  
When mood symptoms are significantly impairing 
function then SSRI therapy is used. An anxiolytic like 
alprazolam can be used for such symptoms not relieved 
by the SSRI medication.  
 Step 3:  
If not responsive to above said treatment GnRH agonists 
is recommended. This would not be done in an 
adolescent without consultation with a gynaecologist. 
36
 
UNANI TREATMENT 
There are different types of Unani medicines which are 
being prescribed for the treatment of premenstrual 
syndrome. 
 According to Ibn Sena, the menstruation which 
occurs as a result of generalized edema is treated by 
venesection (fasd). He further mentioned that its 
treatment should be according to cause. If the cause 
is heat (hiddat) and dominance of bile then it is best 
treated by evacuation (istefragh) of bile especially 
by Shahtara (fumaria officinalis) and halela 
(Terminalia Chebula) because they both have 
astringent property also. If retention of fluid is the 
reason then it is excreted through skin by using 
drugs such as Samaghe arbi(Acacia Arabica) and 
Kateera (Sterculia Urens). If the cause is weakness 
of uterus then astringent drugs along with uterine 
tonics are prescribed.
10
 
 Zakaria Al Razi described drugs having diuretic and 
emmenagogue properties and also included Jund 
bedaster (Castoreum), Tukhme Karafs (Apium 
Graveolens, Heel Kalan (Amomum Subulatum), 
Habbe Balsan (Commiphora Opobalsamum) in this 
group.
11
 
 According to Ghulam Jeelani and Ajmal Khan 
following formulations having diuretic and 
emmenogogue actions are beneficial if used for 7 to 
10 days before menstruation. 
1. Gule Khatmi (Althaea Officinalis), Tukhme Turb 
(Raphanus Sativus), Mushktiramashi (Mentha 
Pulegium), Parsyaoshan (Adiantum Cappilus 
Veneris), Mako ( Solanum Nigrum), each 5 gram is 
taken and decoction is prepared to which 1 gm 
Jawakhar (Pottasium carbonate) is added and used 
for 7 days before menstruation. 
2. Sufoof Mudir Haiz is also useful which has the 
following ingredients: Revand chini (Rheum 
emodi), Shora qalmi (Pottasium Nitrate), Jawakhar 
(Pottasium Carbonate), Zeera Safaid (Cuminum 
Cyminum) and sugar each 12 grams is grinded to 
prepare fine powder and used as 7 grams.
12,13
 
CONCLUSION 
Premenstrual syndrome have unknown multifactorial 
causes but highly treatable disorders. Herbal medicines 
play important role for managing the symptoms of PMS. 
PMS affects the quality of life for many women of 
reproductive age. Pharmacological treatments having 
limited efficacy and substantial side effects. Lifestyle 
changes, dietary modifications, complementary 
therapies and prescription medications reduce the 
symptoms of premenstrual syndrome (PMS). Lifestyle 
changes include regular exercise, quit smoking, reduce 
intake of salt and caffeine and getting sufficient sleep. 
Dietary supplements are helpful in reducing symptoms 
of premenstrual syndrome. Some scientific studies prove 
the effectiveness of herbs to help reduce the effects of 
PMS and report relief of PMS symptoms with the use of 
herbs such as evening primrose oil and saffron.  Unani 
can offer a great benefit to the female population by 
improving her psychosocial as well as physical health 
which ultimately contributes to a healthy society. 
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